Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

December 11, 2018

Alnylam, Silence Therapeutics settle patent dispute

RNAi therapeutics firm Alnylam Pharmaceuticals has entered into a settlement and license agreement with Silence Therapeutics, a biotechnology company that develops gene therapeutic technology based on RNA interference.

Alnylam, Silence Therapeutics settle patent dispute